Key result
Targeting calcium-handling proteins offers key therapeutic potential to alter heart failure and arrhythmia progression.
This review highlights the central role of defective calcium handling in heart failure and arrhythmias, emphasizing the potential of calcium-targeted therapeutics to alter the natural history of these diseases.
Despite advances in pharmacologic and procedural therapies, heart failure (HF) and cardiac arrhythmias remain significant global health burdens, highlighting the urgent need for novel therapeutic strategies. Defective Ca 2+ handling in cardiac myocytes is recognized as a central pathogenic mechanism underlying both heart failure and atrial and ventricular arrhythmias. In this review, we critically assess the current state of research on Ca 2+ -handling proteins and their role in causing heart failure and arrhythmias, highlighting therapeutic implications. Recent paradigm-shifting discoveries, clinical trial outcomes, and challenges of targeting Ca 2+ -handling proteins are examined. As outlined in this review, an improved understanding of the relevant proteins and their differential expression and function in human health and disease is crucial for developing Ca 2+ handling–targeted therapeutics that can fundamentally alter the natural history of heart failure and arrhythmias.
No takes yet. Share an insight, caveat, or question.
Redel‐Traub et al. (2025) conducted a review in Heart failure and cardiac arrhythmias. Calcium handling-targeted therapeutics was evaluated. Targeting calcium-handling proteins is crucial for developing therapeutics that can fundamentally alter the natural history of heart failure and arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: